Compare EPR Properties (EPR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Neurocrine Biosciences Inc — how do they compare? EPR Properties trades at $61.91 (market cap $4.60B), while Neurocrine Biosciences Inc trades at $172.26 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.8× EPR Properties's market cap, and EPR Properties pays a 6.19% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| EPR | NBIX | |
|---|---|---|
Market Cap | $4.60B | $17.30B |
Sector | Real Estate | Health |
52-Week High | $60.81 | $180.55 |
52-Week Low | $48.71 | $123.10 |
Enterprise Value | $7.66B | $16.39B |
Dividend Yield | 6.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $61.76, up 3.73% today, with a bullish technical signal from moving averages and recent breakout above key levels. The REIT shows strong profitability with 39.93% net income margin and consistent dividend payments, though Q1 2026 EPS slightly missed expectations. Recent news highlights monthly dividend declarations and a $315 million Six Flags acquisition diversifying its experiential portfolio.
Outlook remains positive with analyst consensus target of $63.25 offering modest upside, supported by 99% occupancy and stable cash flows. Risks include economic sensitivity of entertainment assets and potential interest rate impacts on REIT valuations. The stock presents a balance of income and growth for investors seeking REIT exposure.
Neurocrine Biosciences (NBIX) trades at $172.14, up 0.09% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 98.17% gross margins and 21.55% net income margin, supported by revenue growth from $2.86B to $3.1B projected. Recent news highlights pipeline advancements including Phase 2 studies and positive clinical data presentations at ENDO 2026.
NBIX presents compelling investment potential with 86% analyst buy ratings and $195.75 consensus target, offering 14% upside. Key catalysts include Q2 earnings on July 30 and continued pipeline execution. Risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's valuation at 26.47 P/E appears reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
